More Patents for New Forms Issued to Generics

There are some more patents issued by the Indian Patent Office to generic companies for new form of known drug substances.

1. Teva Pharmaceutical Industries received Indian Patent No. 210420 for novel hydrate forms of alendronate sodium having water content of 1.35% to 11.7%. Patent was issued last year in October by the Mumbai Patent Office against the application no. 497/MUMNP/2005 which is national phase application of WO 2000/012517. The WO disclosure do not made any data suggesting improved efficacy over the known substance.
2. Indian Patent No. 219014 issued to Torrent Pharmaceuticals Ltd. for Form T1 of nebivolol and its pharmaceutically acceptable salts against the mail-box application no. 811/MUM/2004. The patent issued earlier this year in April. Equivalent WO 2006025070 does not disclose any data suggesting improved efficacy over the known form.
3. Indian Patent No. 212951 for polymorph Form I and 2 of desloratadine hemifumarate issued to Sandoz against the application no. 139/CHENP/2005 which is national phase application of WO 2004012738. The WO disclosure gives no data suggesting improved efficacy over the known form.
4. Indian Patent No. 219489 for amorphous and crystalline forms of losartan potassium issued to Teva Pharmaceutical Industries against the mail-box application no. 1286/DELNP/2004 which is national phase application of WO 2003048135. The WO disclosure does not suggest any data relating to improved efficacy over the known form.

Note: Above information is based on title and abstract available on official website of Indian Patent Office not on issued claims.